Copyright
©The Author(s) 2015.
World J Gastroenterol. Apr 7, 2015; 21(13): 3850-3859
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3850
Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.3850
Ref. | Treatment | n | D | DFS | OS | Toxicities G3-G4 |
Park et al[17] | XP vs XP/XRT/XP | 458 | D2 | 0.74 (0.52-1.05) | 1.13 (0.77-1.64) | N 12%, V 3% in both groups |
Kim et al[19] | FL/FL + RT/FL vs FL | 90 | D2 | 60.9% vs 50.0% | 65.2% vs 54.6% | Hem 25%, GI 11.4% vs Hem 19.6%, GI 17.4% |
Zhu et al[20] | FL/FL + IMRT/FL vs FL | 404 | D2 | 1.35 (1.03-1.78) | 1.24 (0.94-1.65) | Leuco 7.5%, N 2.7% vs Leuco 7.3%, N 0% |
- Citation: Jácome AA, Sankarankutty AK, dos Santos JS. Adjuvant therapy for gastric cancer: What have we learned since INT0116? World J Gastroenterol 2015; 21(13): 3850-3859
- URL: https://www.wjgnet.com/1007-9327/full/v21/i13/3850.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i13.3850